Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo
Important Safety Information | Patient Site
Prescribing Information
    • Why NovoSeven® RT?
    • Pharmacology
    • Congenital Hemophilia A & B with Inhibitors
    • Breakthrough Bleeds
    • Acquired Hemophilia
    • Congenital Factor VII Deficiency
    • Glanzmann's Thrombasthenia
    • Hospital Overview
    • Clinical Pathway for Emergent Bleeds
    • Clinical Pathway for Acquired Hemophilia
    • Hospital Pharmacies
    • Dosing Calculator
    • Quick Reference
    • Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
NovoSeven® RT (coagulation Factor VIIa, recombinant) logo

Indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital factor VII (FVII) deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, and in adults with acquired hemophilia.

Prescribing Information
Important Safety Information | Patient Site
Congenital
hemophilia A or B
with inhibitors
Congenital
hemophilia A or B
with inhibitors

Chase has
CHAwI

Congenital
hemophilia A or B
with inhibitors

Chase has
CHAwI

NovoSeven® RT is the only rFVIIa approved for congenital hemophilia A or B with inhibitors across all age groups and boasts 30+ years of clinical safety and efficacy data.1,2

See efficacy data
See pivotal safety data
See efficacy data
See pivotal safety data

Effective bleed control with proven trial results and real-world experience

Efficacy seen in Lusher et al3

See study design
Muscle bleeds pie chart

Muscle bleeds
N=29

Joint bleeds pie chart

Joint bleeds
N=145

Efficacy seen in adept™24

See study design
Target joint, mucocutaneous, muscle, and other bleeding episodes pie chart

All bleed locations
at 12 hours
N=69

One of the largest clinical trials conducted in patients with CHwI

Consistent efficacy seen in joint, target joint, mucocutaneous, muscle, and other bleeding episodes

98% effective bleed control in patients ≤18 years, based on real-world experience5

 

NovoSeven® RT controls joint bleeds fast1,3,6,a

Your patients expect fast resolution of joint bleeds. NovoSeven® RT controls bleeds in as few as 5 hours with a median of 2 doses.3,6,b

See study design
5 hr pie chart

Quickly achieves maximum activity

NovoSeven® RT achieved maximum activity within
5-10 minutes of infusion.6,c

See study design
5-10 min pie chart

NovoSeven® RT can be readministered as quickly as every 2 hours compared with 6 to 12 hours for FEIBA®.1,7

aIn patients with hemophilia A or B with inhibitors.3
bCalculation of 5 hours is based on 2.2 doses at 2-hour interval.
cFVIIa activity IU/mL.

Bleeds happen. Treat fast.


NovoSeven® RT is a first choice for treating breakthrough bleeding for CHAwI patients on emicizumab and was the only recombinant factor used for breakthrough bleeds in patients with inhibitors in the Hemlibra® pivotal clinical trials.8,9

Review real-world data on breakthrough bleeds

 

Actor portrayal

 

Bleeds happen. Treat fast.


NovoSeven® RT is a first choice for treating breakthrough bleeding for CHAwI patients on emicizumab and was the only recombinant factor used for breakthrough bleeds in patients with inhibitors in the Hemlibra® pivotal clinical trials.8,9

Review real-world data on breakthrough bleeds

Actor portrayal

Bleeds happen. Treat fast.


NovoSeven® RT is a first choice for treating breakthrough bleeding for CHAwI patients on emicizumab and was the only recombinant factor used for breakthrough bleeds in patients with inhibitors in the Hemlibra® pivotal clinical trials.8,9

Review real-world data on breakthrough bleeds

 

Actor Portrayal


Effectiveness in surgeries and procedures

NovoSeven® RT is the only bypassing agent approved for continuous infusion and with controlled clinical trials supporting its efficacy during and after surgery in patients with CHwI.1,2,7,8,d

See study design

Results of a prospective, randomized trial show the effectiveness of NovoSeven® RT. Percentage of patients with adequate hemostasis7:

Effectiveness of NovoSeven® RT during surgery
Effectiveness of NovoSeven® RT postoperative day 2
Effectiveness of NovoSeven® RT postoperative day 5
Effectiveness of NovoSeven® RT postoperative day 6-26
Effectiveness of NovoSeven® RT during surgery
Effectiveness of NovoSeven® RT postoperative day 2
Effectiveness of NovoSeven® RT postoperative day 5
Effectiveness of NovoSeven® RT postoperative day 6-26

The postoperative period: essential to surgical success

Adapted from Shapiro et al.7,d

dIn patients with hemophilia A or B with inhibitors. Actual length of postoperative period may vary.


Established safety profile

Pivotal studies and real world data show a low rate of thrombotic events.

Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.1 Thrombotic adverse reactions in pivotal clinical trials occurred in 0.2% of bleeding episodes in patients with congenital hemophilia with inhibitors.1,e

See Important Safety Information, including Boxed Warning.

eIn patients with congenital hemophilia.

Data from pivotal clinical trials1

NovoSeven® RT safety data

Occurrence of thrombotic events

NovoSeven® RT is the only rFVIIa that was used in the Hemlibra® pivotal clinical trials.

NovoSeven® RT was used safely in 61 patients CHAwI treating with Hemlibra in 3 separate pivotal trials: HAVEN 1, 2, and 4.10,11,f

180 bleeds were treated with NovoSeven® RT only in HAVEN 1

No SAEs, TMAs, or TEs were observed with use of NovoSeven® RT alone in HAVEN 1, 2, and 4

No new or unexpected safety concerns were observed with use of NovoSeven® RT in conjunction with Hemlibra

Two cases of TMA occurred in patients treating with Hemlibra while receiving FEIBA® and NovoSeven® RT. Simultaneous use of NovoSeven® RT and FEIBA should be avoided

Secure icon

MASAC recommends rFVIIa as a first option to treat acute bleeding episodes in patients with CHAwI on emicizumab—aPCC should be avoided if possible.9

These MASAC recommendations were created based in part on the safe use of NovoSeven® RT with Hemlibra in 3 of the pivotal HAVEN clinical trials.9,10

MASAC=Medical and Scientific Advisory Council; rFVIIa=recombinant activated factor VII; SAE=serious adverse event; TMA=thrombotic microangiopathy; TE=thrombotic event.
fThe analysis included bleeding episodes in the HAVEN 1, HAVEN 2, and HAVEN 4 clinical trials for which patients with CHAwI on emicizumab prophylaxis (at the labeled dose) used rFVIIa. Initial individual dosing with rFVIIa, dosing intervals, and cumulative dosing were evaluated. All adverse events reported in each of the 3 trials, including available narratives, were assessed. The cutoff date for the data presented was September 8, 2017.

Two people standing, having their arm, nose, and knee highlighted

 

Teach patients the signs and symptoms of internal bleeds

This educational resource may be able to help your patients quickly identify bleeds when and where they happen. Use this tool to help your patients identify breakthrough bleeds which may require treament on-the-go.

Try the Bleed ID Tool

NovoSeven® RT is manufactured with safety in mind

NovoSeven® RT is not made from human serum or proteins. Recombinant manufacturing minimizes the possibility of viral contamination.1,12

 

Review recombinant safety info
Study design
Test tube with blood droplet and plus sign icon

Lusher, et al
Randomized, double-blind, parallel group, international multicenter trial

Patients: Patients with hemophilia A and B with and without an inhibitor (N=84).

Study design: Patients were given NovoSeven® RT 35 or 70 mcg/kg at dosing intervals of 2 to 3 hours.

Primary endpoint: Comparing the efficacy between two different doses of NovoSeven® RT in the treatment of patients with hemophilia A or B, with or without inhibitors, for the treatment of joint, muscle, and mucocutaneous bleeds.

Secondary endpoint: Compare short-term safety between two doses of NovoSeven® RT and monitor patients for the development of inhibitors to NovoSeven® RT and to any contaminants included in the preparation of NovoSeven® RT.

Lentz, et al
adept™2 phase 3 trial 

Patients randomized: Patients ≥12 years of age with hemophilia A with inhibitors (N=66) or hemophilia B with inhibitors (N=6) who have experienced at least 5 bleeds during treatment prior to entering the trial. 

Study design: A 12-month, international, multicenter, randomized, double-blind, active-controlled, crossover, confirmatory phase 3 trial. Primarily done in the home setting, treatment of bleeding episodes were randomized, either treated with 1 to 3 doses of vatreptacog alfa (340 bleeding episodes) at 80 mcg/kg or 1 to 3 doses of NovoSeven® RT (2227 bleeding episodes) at 90 mcg/kg.

Primary endpoint: Effective bleed control, which was defined as no additional hemostatic treatment needed (other than the original medication) within 12 hours after first dose. 

Secondary endpoint: Effective and sustained bleed control at 1 and 2 days after initial dose, number of doses of trial product for each bleed, and changes in pain assessment.4

Bysted, et al
Randomized, double-blind bioequivalence trial

Patients randomized: Healthy participants ages 18-45 (N=22).

Study design: A single-center, randomized, double-blind, two-way crossover study. Participants received 1 intravenous bolus injection each of NovoSeven® RT and NovoSeven® RT. Both bolus injections were 90 mcg/kg and occurred 2 to 3 weeks apart at consecutive visits. While the comparison is not shown for FVIIa, activity for NovoSeven® RT was the bioequivalent range of that for NovoSeven® RT during this period.

Primary endpoint: Demonstrate bioequivalence between NovoSeven® RT and a new formulation, stable up to 77˚F.

Secondary endpoint: Comparing the area under the plasma activity-time curve and the mean residence time between NovoSeven® RT and the new formulation.6

Shapiro, et al
Prospective, randomized trial evaluating efficacy in surgery

Patients randomized: Patients with hemophilia A with inhibitors (N=25), hemophilia B with inhibitors (N=3) and acquired hemophilia (N=1).

Study design: This trial compared 35 mcg/kg with 90 mcg/kg rFVIIa. Patients with inhibitors (FVIII, N=26; FIX, N=3) were given NovoSeven® RT immediately prior to incision, then every 2 hours intraoperatively or as needed, followed by every 2 hours from wound closure in the first 48 hours, then every 2 to 6 hours through day 5. Beyond day 5, patients were treated with open-label 90 mcg/kg until discharge of the investigator. A total of 29 patients underwent 11 major and 18 minor procedures. Data shown are from the 90 mcg/kg group.

Primary endpoint: Demonstrated hemostasis at the surgical site during operation, after the wound is closed, 8 hours after the wound is closed and once daily for five days after the procedure.7

Doctor comforting a patient

Explore how hospitals use NovoSeven® RT to treat CHwI.

See more about hospital use

When would you treat a breakthrough bleed?

Learn more about assessing
breakthrough bleeds
Patient education materials

Find resources that can help your patients with inhibitors.

View Patient Education

Selected Important Safety Information for NovoSeven® RT

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events

Indications and Usage

NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance
  • Patients with congenital hemophilia receiving concomitant treatment with aPCCs (activated prothrombin complex concentrates), older patients particularly with acquired hemophilia and receiving other hemostatic agents, and patients with a history of cardiac and vascular disease may have an increased risk of developing thrombotic events
  • Hypersensitivity reactions, including anaphylaxis, can occur with NovoSeven® RT. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII

Please click here for NovoSeven® RT Prescribing Information, including Boxed Warning.

References

1.    NovoSeven RT. Package insert. Novo Nordisk Inc; 2020.

2.   SEVENFACT. Package insert. HEMA Biologics; 2022.

3.   Lusher JM, Roberts HR, Davignon G, et al; and rFVIIa Study Group. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4(6):790-798.

4.   Lentz SR, Ehrenforth S, Abdul Karim F, et al; adept™2 investigators. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. J Thromb Haemost. 2014;12(8):1244-1253.

5.   Neufeld EJ, Saxena K, Kessler CM, et al. Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: the experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004-2008). Pediatr Blood Cancer. 2013;60(7):1178-1183.

6.   Bysted BV, Scharling B, Moller T, Hansen BL. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation. Haemophilia. 2007;13(5):527-532.

7.   FEIBA. Package insert. Baxter Healthcare Corporation; 2023.

8.   MASAC recommendation on the use and management of emicizumab-kxwh (Hemlibra®) for hemophilia A with and without inhibitors. MASAC Document #268. Accessed June 20, 2023. 
https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-268-recommendation-on-the-use-and-management-of-emicizumab-kxwh-hemlibrar-for-hemophilia-a-with-and-without-inhibitors

9.   Levy GG, Asikanius E, Kuebler P, et al. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program. J Thromb Haemost. 2019;17(9):1470-1477.

10. Shapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998;80(5):773-778.

11. National Hemophilia Foundation. Recommendation on the use and management of emicizumab-kxwh (hemlibra®) for hemophilia a with and without inhibitors, #258. New York, NY: National Hemophilia Foundation; 2020.

12. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818 and appendix.

13.  National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders, #263. New York, NY: National Hemophilia Foundation; 2020.

Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders


NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2023 Novo Nordisk All rights reserved.  US23NSVN00011  August 2023

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials